A new approach to the hormonal treatment of impotentia erectionis

The influence of oraly administered synthetic oxytocin (Syntocinon, Sandoz) on the impotentia erectionis has been studied in a double-blind trial in comparison to placebo. Twenty-nine out-patients divided into 3 groups were treated for a minimum of 7 weeks. Nine patients were given 300 IU daily, ten patients 600 IU daily and further 10 patients placebo. The treatment with 300 IU of oxytocin daily has shown the best therapeutic results. The difference between this group and the placebo group was statistically significant regarding the overall parameters sexual interest and sexual capability (P less than 0.05) and P less than 0.10 respectively). The daily oral dose of 600 IU produced no significant therapeutic effect. Oxytocin in both dosage schedules was well tolerated and no untoward side effects were observed.